McKay R G, Fram D B, Hirst J A, Kiernan F J, Primiano C A, Rinaldi M J, Azrin M A, Mitchel J F, Waters D D
Department of Internal Medicine, Hartford Hospital, University of Connecticut 06115.
Cathet Cardiovasc Diagn. 1994 Oct;33(2):181-8. doi: 10.1002/ccd.1810330223.
The presence of intracoronary thrombus significantly increases the risk of conventional balloon angioplasty because of a high incidence of abrupt closure, distal embolization, and no-reflow phenomenon. The purpose of this study was to assess a new technique for treating intracoronary thrombus consisting of the local delivery of urokinase directly to the angioplasty site with a novel, catheter-based, drug delivery system.
The Dispatch catheter is a new local, drug-delivery device that allows for the prolonged infusion of therapeutic agents at an angioplasty site while still maintaining distal coronary perfusion. Six patients with angiographic or clinical evidence of intracoronary thrombus were treated with 150,000 units of urokinase over a 30-min period using this device prior to or following conventional balloon angioplasty and/or directional atherectomy.
Successful delivery of urokinase directly to the angioplasty site was achieved in all 6 patients without hemodynamic or electrocardiographic compromise. In all six cases, local urokinase therapy resulted in complete dissolution of angiographic intracoronary thrombus and/or reduction of the coronary stenosis. Limited ischemia due to side-branch occlusion by the catheter's coils was noted in one patient. Distal embolization or no-reflow phenomenon were not observed in any case.
The local drug-delivery catheter used in this study was able to successfully and rapidly achieve intracoronary thrombolysis by delivering limited quantities of urokinase directly to the angioplasty site, while still maintaining distal coronary perfusion. This technique of local, thrombolytic drug delivery may be useful in the percutaneous treatment of intracoronary thrombus and thrombus-containing stenoses.
冠状动脉内血栓的存在显著增加了传统球囊血管成形术的风险,这是因为急性血管闭塞、远端栓塞和无复流现象的发生率很高。本研究的目的是评估一种治疗冠状动脉内血栓的新技术,该技术通过一种新型的基于导管的药物输送系统将尿激酶直接局部输送到血管成形术部位。
Dispatch导管是一种新型的局部药物输送装置,它能够在血管成形术部位长时间输注治疗药物,同时仍能维持冠状动脉远端灌注。6例有冠状动脉内血栓造影或临床证据的患者在传统球囊血管成形术和/或定向旋切术之前或之后,使用该装置在30分钟内输注150,000单位尿激酶进行治疗。
所有6例患者均成功地将尿激酶直接输送到血管成形术部位,且未出现血流动力学或心电图异常。在所有6例病例中,局部尿激酶治疗均导致冠状动脉内血栓造影完全溶解和/或冠状动脉狭窄减轻。1例患者出现因导管线圈阻塞侧支而导致的局限性缺血。未观察到任何远端栓塞或无复流现象。
本研究中使用的局部药物输送导管能够通过将有限量的尿激酶直接输送到血管成形术部位,成功且迅速地实现冠状动脉内溶栓,同时仍维持冠状动脉远端灌注。这种局部溶栓药物输送技术可能对冠状动脉内血栓和含血栓狭窄的经皮治疗有用。